Blar i Bergen Open Research Archive på forfatter "Brekke, Jorunn"
-
Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival
Rahman, Mohummad Aminur; Gras Navarro, Andrea; Brekke, Jorunn; Engelsen, Agnete; Bindesbøll, Christian; Sarowar, Shahin; Bahador, Marzieh; Bifulco, Ersilia; Goplen, Dorota; Waha, Andreas; Lie, Stein Atle; Gjertsen, Bjørn Tore; Selheim, Frode; Enger, Per Øyvind; Simonsen, Anne; Enger, Martha Chekenya (Peer reviewed; Journal article, 2019-08-15)Background Resistance to temozolomide (TMZ) is due in part to enhanced DNA repair mediated by high expression of O6-methyl guanine DNA methyltransferase (MGMT) that is often characterised by unmethylated promoter. Here, ... -
Sequential bortezomib and temozolomide treatment promotes immunological responses in glioblastoma patients with positive clinical outcomes: A phase 1B study
Rahman, Mohummad Aminur; Brekke, Jorunn; Arnesen, Victoria Smith; Hannisdal, Marianne; Navarro, Andrea Gras; Waha, Andreas; Herfindal, Lars; Rygh, Cecilie Brekke; Bratland, Eirik; Brandal, Petter; Haász, Judit; Oltedal, Leif; Miletic, Hrvoje; Lundervold, Arvid; Lie, Stein Atle; Goplen, Dorota; Chekenya, Martha (Journal article; Peer reviewed, 2020)Background Glioblastoma (GBM) is an aggressive malignant brain tumor where median survival is approximately 15 months after best available multimodal treatment. Recurrence is inevitable, largely due to O6 methylguanine ... -
Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions
Blakstad, Hanne Kristin; Brekke, Jorunn; Rahman, Mohummad Aminur; Arnesen, Victoria Smith; Miletic, Hrvoje; Brandal, Petter; Lie, Stein Atle; Enger, Martha; Goplen, Dorota (Journal article; Peer reviewed, 2023-02-02)Therapy of recurrent glioblastoma (GBM) is challenging due to lack of standard treatment. We investigated physicians’ treatment choice at recurrence and prognostic and predictive factors for survival in GBM patients from ...